SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Small proteins (3458)
(-)
Fold: Knottins (small inhibitors, toxins, lectins) (761)
(-)
Superfamily: EGF/Laminin (347)
(-)
Family: EGF-type module (304)
(-)
Protein domain: automated matches (66)
(-)
Human (Homo sapiens) [TaxId: 9606] (66)
1W0YL:87-142TF7A_3771 COMPLEX
1W2KL:87-142TF7A_4380 COMPLEX
1W7XL:FACTOR7 - 413 COMPLEX
1W8BL:FACTOR7 - 413 COMPLEX
1Z6EL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
2AERL:87-142CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2BMGA:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
2BOKL:FACTOR XA - CATION
2BQ6A:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
2BQ7A:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
2BQWA:CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
2BZ6L:ORALLY AVAILABLE FACTOR7A INHIBITOR
2EC9L:87-142CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2FZZL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE
2G00L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE
2JKHL:FACTOR XA - CATION INHIBITOR COMPLEX
2P16L:FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
2P3TA:CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE
2P3UA:CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
2P93L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
2P94L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE
2P95L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
2Q1JB:THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
2VVCK:; L:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVUL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVVL:AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2VWLL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWMK:; L:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWNL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWOL:AMINOPYRROLIDINE FACTOR XA INHIBITOR
2W26B:FACTOR XA IN COMPLEX WITH BAY59-7939
2W3IB:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2
2W3KB:CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1
2WPHE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT
2WPIE:FACTOR IXA SUPERACTIVE DOUBLE MUTANT
2WPJE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED
2WPKE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED
2WPLE:FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED
2WPME:FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED
2XBVL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBWL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBXL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBYL:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC0L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC4L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC5L:FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2Y5FL:FACTOR XA - CATION INHIBITOR COMPLEX
2Y5GL:FACTOR XA - CATION INHIBITOR COMPLEX
2Y5HL:FACTOR XA - CATION INHIBITOR COMPLEX
3CENL:FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE
3CS7L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3ENSA:90-126; A:127-178; C:89-126; C:127-178CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
3FFGL:FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3HPTA:90-126; A:127-178; C:89-126; C:127-178CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
3K9XA:90-126; A:127-178; C:94-126; C:127-178X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3KQBL:FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
3KQCL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQDL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQEL:FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3M36L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[3-(AMINOMETHYL) PHENYL]-N-[3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC423)
3M37L:FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[2-(AMINOMETHYL) PHENYL]-N-(3-FLUORO-2'-SULFAMOYLBIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC602)
3SW2A:X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH 6-CHLORO-N-((3S)-2-OXO-1-(2-OXO-2-((5S)-8-OXO-5,6-DIHYDRO-1H-1,5-METHANOPYRIDO[1,2-A][1,5]DIAZOCIN-3(2H,4H,8H)-YL)ETHYL)PIPERIDIN-3-YL)NAPHTHALENE-2-SULFONAMIDE
3TH2L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
3TH3L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
3TH4L:87-142MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
4NGAL:FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-[2-(PROPAN-2-YLSULFONYL)BENZYL]ETHANAMIDE